Abstract: A shock wave, which carries energy and can propagate through a medium, is a type of continuous transmitted sonic wave with a frequency of 16 Hz-20 MHz. It is accompanied by processes involving rapid energy transformations. The energy associated with shock waves has been harnessed and used for various applications in medical science. High-energy extracorporeal shock wave therapy is the most successful application of shock waves, and has been used to disintegrate urolithiasis for 30 years. At lower energy levels, however, shock waves have enhanced expression of vascular endothelial growth factor, endothelial nitric oxide synthase, proliferating cell nuclear antigen, chemoattractant factors and recruitment of progenitor cells; shock waves have also improved tissue regeneration. Low-energy shock wave therapy has been used clinically with musculoskeletal disorders, ischemic cardiovascular disorders and erectile dysfunction, through the mechanisms of neovascularization, anti-inflammation and tissue regeneration. Furthermore, low-energy shock waves have been proposed to temporarily increase tissue permeability and facilitate intravesical drug delivery. The present review article provides information on the basics of shock wave physics, mechanisms of action on the biological system and potential applications in functional urology.
Abbreviations & Acronyms
BoNT/A = botulinum neurotoxin serotype A COX-2 = cyclooxygenase-2 CPPS = chronic pelvic pain syndrome CYP = cyclophosphamide DU = detrusor underactivity ED = erectile dysfunction EFD = energetic flux density eNOS = endothelial nitric oxide synthase ERK = extracellular signalregulated kinase ESWT = extracorporeal shock wave therapy INF-c = interferon-c IIEF-EF = International Index of Erectile Function -Erectile Function IL = interleukin iNOS = inducible nitric oxide synthase LESW = low-energy shock wave MMP = matrix metallopeptidase NGF = nerve growth factor NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index NO = nitric oxide PDE5i = phosphodiesterase type 5 inhibitor RCT = randomized controlled trial SW = shock wave TGF = transforming growth factor TNF-α = tumor necrosis factor-α UAB = underactive bladder VEGF = vascular endothelial growth factor Currently, ESWT is applied in a wide range of different disorders in orthopedics (tendinopathies, cartilage repair and bone healing), dermatology (wound healing, fire burns, ulcers and diabetic foot ulcers), neurology (spasticity or spastic hypertonia and neuron protection), dentistry (alveolar bone regeneration and periodontitis), urology (Peyronie's disease and ED) and stem cell treatments (Peyronie's disease and swine myocardial infarction model). [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The history and development of ESWT are summarized in Figure 1 . ESWT might also be a promising method for use in functional urology.
Physical characteristics of SW
The term "shock wave" indicates a high-energy sound wave that terminates in a burst of energy, similar to a mini-explosion. SWs are sound waves that carry energy from an area of positive pressure to an area of negative pressure, and requires a medium (either water or a coupling gel) for propagation in human use. In nature, SWs are created by explosive events, such as lightning strikes and volcanic eruptions. SWs can also be artificially produced, by supersonic aircraft breaking the sound barrier or bomb explosions. In medical use, SW are generated extracorporeally by three types of generators: electrohydraulic, electromagnetic and piezoelectric (Fig. 2a) . The generator induces micro-explosive acoustic energy, focused by concentrating reflectors, and releases a mechanical, chemical or electrical energy toward the target body tissues. 21 , 34 The characteristics of a SW are high peak pressure (up to 100 MPa), rapid rise (<10 ns), short duration (<10 ms) and broad frequency spectrum (in the range of 16 Hz-20 MHz; Fig. 2b) . 16, 35 The acoustic SW energy (such as with focused ESWT) or ballistic SW energy (such as with radial ESWT) transfers into the target tissue with various focal volumes, depths of penetration, levels of EFD (mJ/ mm 2 ) and total energy administration. The intensity of SWs induces a positive pressure followed by energy discharged close to the target tissue, causing the biological effects. Ultrasound waves, which are typically biphasic and have a peak pressure of 0.5 bar, are different from SWs.
Mechanism of ESWT
The biological mechanism of ESWT is still unclear, but it has been continuously improved on. Four reaction phases of SWs on tissue have been postulated by Haupt: 36 1 The physical phase. Positive pressure can trigger absorption, reflection, refraction and/or transmission of energy into tissues or cells. 37 Tensile force is induced by the negative pressure of SW, producing effects of cavitation (formation and movement of bubbles in a fluid), ionization of molecules and an increase in cell membrane permeability. These physical forces transfer the acoustic signal into a biological reaction through a mechanotransduction pathway that adjusts the ERK signal transduction or focal adhesion kinase, and regulates gene expression in the nucleus. 16 VEGF and proliferating cell nuclear antigen, as well as causing neovascularization and improving tissue regeneration. 42 However, it should be noted that high energy levels (>0.12 mJ/mm 2 ) of SW induce irreversible alterations to the cell structure and organelles. 19, 34, 43, 44 Low energy levels (<0.12 mJ/mm 2 ) of SW, in contrast, induce cell membrane modifications and functional changes, and conduct a series of cell signaling and activation of biological processes, such as cell proliferation, angiogenesis, peripheral nerve regeneration, increased cell permeability and anti-inflammation. 16, 19, 34, 35 How LESW works LESWs have effects on induction of cell proliferation, angiogenesis, nerve regeneration, anti-inflammation and a temporary increase of membrane permeability, through the modulation of various mechanisms, depending on tissue type and condition.
Cell proliferation
At lower energy levels, SWs enhance expression of VEGF, eNOS, proliferating cell nuclear antigen, TGF-b1, fibroblast growth factor 2, chemoattractant factors and recruitment of progenitor cells, and improves tissue regeneration. Cell proliferation is the first step through LESW to facilitate tissue regeneration. The biological effect of this is in a 
Angiogenesis
LESW not only induces cell proliferation, but also improves angiogenesis. LESW therapy increases expression of NO and VEGF, which have been shown as important mediators of angiogenesis. 42 LESW induces the expression of angiogenesis-related factors, such as eNOS and VEGF, and induces neovessel growth and tissue regeneration at the tendon-bone junction in rabbits. 42 LESW has been shown to improve myocardial function and blood flow, by increasing capillary density and VEGF expression, in patients with ischemic heart disease. 49 The mechanism of angiogenesis has been suggested to be through mechanosensory complex formation, which includes VEGF receptor 2, vascular endothelial cadherin and platelet endothelial cell adhesion molecule 1, and stimulates phosphorylation of Akt, eNOS and angiogenic gene expression. 50 Angiogenesis-related cytokines, such as eNOS, basic fibroblast growth factor, stromal cell-derived factor 1, and its receptor C-X-C motif chemokine 4, are involved in tissue regeneration in patients with coronary artery disease, as well as in animal models. 51, 52 Nerve regeneration SW has pain relief effects after application to musculoskeletal systems. Previous studies have postulated that ESWT can induce degeneration of intercutaneous nerve fibers, and that this might be responsible for the immediate analgesic effect. However, the question of safety in ESWT has been raised, as some studies observed damage to the myelin sheath by ESWT. [53] [54] [55] Hausdorf et al. applied moderate energy (1500 pulses, energy flux density 0.9 mJ/mm 2 ) on the hind limbs of rabbits; this resulted in a substantial loss of unmyelinated nerve within the femoral nerve of the treated limb. 54 Another study shown an effect, positively correlated with the intensity of the SWs (2000 pulses with 0.08, 0.19 and 0.49 mJ/mm 2 ), of inducing reversible segmental demyelination in large nerve fibers in rats. 55 Different energy intensities of ESWT induce different biological effects. At a lower energy intensity (300 pulses, 0.1 mJ/mm 2 ), ESWT was able to induce a growth-promoting effect in myelinated motor axonal regeneration in autograft sciatic nerve graft rat models. 56 Other studies applied low-energy ESWT to injured spinal cords of Sprague-Dawley rats. 57, 58 In the ESWT group, CD31 and a-SAM expression was promoted, and TUNEL-positive cells were decreased in the injured spinal cord. 58 In addition, the VEGF expression was significant increased in the NeuN-, GFAP and Olig2-labeled cells. The results of these studies show that the neuroprotective effect of VEGF, induced by low-energy ESWT, can reduce axonal damage and cell apoptosis, and consequently lead to better locomotor recovery after spinal cord injury.
Some diseases include traumatic injury or diabetic effects on the function of Schwann cells in the peripheral nervous system. Recent innovations in tissue engineering might be able to differentiate different stem cell populations into Schwann cells. These cells can be transplanted into patients as a potential cell replacement therapy for peripheral neuropathic conditions. 59 Low-energy ESWT has been proven to improve in vitro native Schwann cell isolation and culture without phenotype commitment, and to reduce senescence-associated markers after 15 passages. 60 Another study showed that ESWT had a positive effective on Schwann cell proliferation in vitro. 61 The p75 gene and p-Erk1/2, which are regarded as Schwann cell activation-related markers, were upregulated after ESWT. A combination of ESWT and tissue engineering technologies might be able to achieve cell requirements for clinical therapeutic application.
Anti-inflammation
ESWT also triggers anti-inflammatory action. This action has been shown to be related to the mechanism of "mechanotherapy" that induces different biological reactions' pathways in immunomodulation. 62 In some preclinical studies, LESW significantly decreased infiltration by inflammatory cells (neutrophils and macrophages) in burned skin 63 or skin flaps, 64 ischemic heart muscle 65, 66 and in the urinary bladder. 67, 68 LESW not only decreased the infiltration of macrophages, but also caused inhibition of M1 marker genes (CD80, COX-2, CCL5) in M1 macrophages, and a synergistic effect on M2 marker genes (ALOX15, MRC1, CCL18) in M2 macrophages. 69 This leads to a decreased pro-inflammatory profile in M1 macrophages, and an increase in the presence of M2 macrophages with an antiinflammatory profile. 65, 69, 70 ESWT treatment is also associated with suppression of pro-inflammatory cytokines, chemokines, and MMPs. Pro-inflammatory cytokines (IL-1a, IL-4, IL-6, IL-10, IL-12, IL-13 and INF-c) were significantly suppressed after ESWT in murine models. Chemokines (CCL2, CCL3, CCL4, CCL7, CXCL1, CXCL2, CXCL5) and MMP (MMP-3, MMP-9, MMP-13) were also reduced after ESWT treatment in murine burned skin, skin isografts, and urinary bladders. 63, 67, 71 ESWT at different time-points and energies has showed differing effects on the inflammatory process. Fischer et al. inserted silicone prostheses into submuscular pocket in rats. 72 ESWT was then applied across the implants and the surrounding capsule tissue. Multiple applications of ESWT decreased inflammation through decreased expression of CD68 and Ccl12, which have been associated with inflammatory reactions. 73 Multiple applications of ESWT also led to degradation of the capsule surrounding the implant, at 100 days after SW. This finding was substantiated by the increased expression of MMP2, which breaks down extracellular matrix protein. In contrast, single applications of ESWT showed a capacity to decelerate capsule formation at an early time-point (<35 days after ESWT). 72 Alteration of membrane permeability SW has been shown to temporarily increase tissue permeability, and facilitate delivery of macromolecules or drugs into cells without consequent cytotoxicity. 74, 75 Kodama et al. suggested that SWs might cause a shear force generated by movement of the liquid relative to the cells, temporarily affecting the permeability of the plasma membrane. 74 The impulse (defined as the integral of pressure with duration) of the SW might be an important factor governing the temporary permeability increase that is necessary to deliver macromolecules into cells. 74 SWs result in reversible permeabilization of cells in targeted areas of tissue without undue toxicity, and can deliver molecules of up to 2 000 000 molecular weight into the cytoplasm of cells. 75 The ability to deliver large molecules (megadalton) through cell permeabilization could be applied in gene therapy, where plasmids are usually of this size. 76 Rationale for using LESW in the lower urinary tract
Inflammatory disorders: Non-infectious prostatitis or cystitis Non-bacterial prostatitis and CPPS are common types of prostatitis, affecting 5-10% of the male population. A possible cause of non-bacterial prostatitis might be neurogenic or immunogenic inflammation; this activates prostate-afferent nerves, and induces inflammation, prostate pain and referred pain. The imbalance of the altered androgen receptor hormone condition is one of the factors inducing prostatodynia. An imbalance of cytokines, including INF-c, IL-6, IL-10, TNF-a and IL-1b, also induces an autoimmune process. 77 Previous studies have shown that NGF and cytokines (IL-6 and IL-10) that regulate inflammation might play a role in the pain symptoms experienced by patients with CPPS. 78 Changes of NGF level in EPS occur in proportion to pain severity in expressed prostatic secretions. 79 Many cytokines and growth factors, including TNF-a, IL-1b, TGF-a and TGF-b1, can upregulate NGF production. 80 Previous studies have shown that LESW has protective effects on inflammatory reaction, by lowering the expression of NGF, IL-6, IL-12, TNF-a, COX-2 and iNOS. 67, 68 These effects might be used as a novel therapy in treating non-bacterial prostatitis/ CPPS.
Zimmermann et al. first investigated the effects of ESWT on CPPS. Compared with the control group, ESWT significantly improved pain and micturition, as well as erectile function and quality of life. 81 Al Edwan et al. further demonstrated the maximal effects of LESW (ESWT once a week for 1 month, with a protocol of 2500 pulses on the perineum with total energy flow density 0.25 mJ/mm 2 over 13 min) on the IPSS, NIH-CPSI and the American Urological Association Quality of Life due to Urinary Symptoms scale at 2 weeks; the effect was stabilized until 12 months. 82 There were no significant side-effects in these studies (Table 1) . However, more trials with different protocols to maximize the short-and long-term outcome are required before LESW can be widely applied in non-bacterial prostatitis/CPPS.
In preclinical studies, LESW also showed its potential for relieving inflammatory conditions and overactivity in CYPinduced cystitis in rats. 68 LESW reduced pain behavior in conjunction with downregulation of IL-6 and NGF expression at day 4 (40.9% and 33%, respectively, P < 0.05), as compared with the control. CYP-induced COX-2 expression (38.6%, P < 0.05) and bladder overactivity was reduced by LESW (77.8% increase in intercontraction interval compare with the cystitis group, P < 0.05) at day 8. Using different doses of LESW and CYP, Chen et al. showed that LESW significantly alleviates bladder damage through amelioration of inflammation (decreased expression of IL-12, MMP9, TNF-a, nuclear factor-kB and iNOS) and oxidative stress (decreased nicotinamide adenine dinucleotide phosphate oxidase 1 and NOX-2 expression). 67 Therefore, we suggest that LESW might be a potential option for the treatment of bladder inflammatory conditions and overactivity.
Erectile dysfunction
After the introduction of PDE5i approximately two decades ago, treatment strategies for ED have continued to focus on restoration of natural erection. There is a substantial ED population (30-40%) who are not satisfied with PDE5i treatment. This includes patients taking nitrate medications, those intolerant to the side-effects of PDE5i or those with certain types of ED that are refractory to PDE5i treatment. 83 In 2008, Muller et al. evaluated the impact of SWs on functional and structural changes in erectile tissue in rats. They used radial SWs applied to the penis at varied energy and dose levels, from 1 bar/1000 SW/1 session to 2 bar/2000 SW/3 sessions. Both low and high energy levels in this study resulted in collagenization of corporal smooth muscle, with increased apoptosis. 84 This raised the issue of whether corporal tissue and erectile function would be impaired by SWs. However, the follow-up studies using focused ESWT energy levels on the penis (from 0.06 mJ/mm 2 300 pulses to 0.09 mJ/mm 2 1000 pulses) showed different results. 61, 85 In a diabetes mellitusassociated ED rat model, ESWT partially, but significantly, alleviated diabetes mellitus-associated defects by recruiting the mesenchymal stem cells into penis corporal tissue, thus regenerating n-NOS-positive nerves, smooth muscle and endothelium. 85 Low-energy ESWT-induced progenitor cell recruitment and Schwann cell proliferation also led to nerve regeneration and angiogenesis in a pelvic neurovascular injured rat model. 61 Clinical application of LESW was initially focused on patients who respond to PDE5i therapy. Vardi et al. first reported that LESW had a positive clinical effect in restoring erectile function in a RCT. 86 The SWs were delivered into five locations including the distal, mid and proximal penile shaft, and the left and right crura. Each location received 300 shocks at 0.09 mJ/mm 2 , which resulted in 1500 shocks per section. The 9-week treatment protocol comprised of two treatment sessions per week for 3 weeks that were repeated after a 3-week no treatment interval. The IIEF-EF domain score in the treated group increased by 6.7 points, which was a significant difference from the sham group (3 points, P = 0.0322). No side-effects, such as pain or ecchymosis, were reported in the series. A meta-analysis of 14 studies including 833 patients with ED, receiving ESWT from 2005 to 2015, showed that LESW significantly improved the IIEF score and erection hardness score (risk difference 0.16, P < 0.01) in ED patients without Peyronie's disease for at least 3 months (mean difference 2.36; P < 0.0001). 87 Therapeutic efficacy was better in mild-to-moderate ED patients, or in the ESWT combined with PDE5i usage group, regardless of disease severity. Another meta-analysis focused on seven RCTs, involving 602 PDE5i responders with an average follow up of 19.8 months. Pooled change in the IIEF-EF score, from baseline to follow up after LESW, improved significantly compared with the sham group (6.4 points; 95% CI 1.78-11.02; P < 0.001 vs 1.65 points; 95% CI 0.92-2.39; P < 0.0001; between-group difference P = 0.047). 88 For patients with severe ED who are non-responsive to PDE5i, LESW has been shown to be able to allow these patients to become responders. 89 In a prospective doubleblind RCT of patients with vasculogenic ED who were not taking PDE5i due to lack of effect, 54% of those receiving LESW in combination with PDE5i achieved hard enough erections, in comparison with 0% of the sham group (PDE5i only). The IIEF-EF score increased from 7 to 13 at follow up in the LESW group, compared with the incremental improvement (from 8 to 8.5) in the sham group. 90 This indicated that even with severe ED patients who were non-responders to PDE5i, SW therapy was able to allow nearly half of them to Table 2 .
Tissue regeneration in cryoinjured UABs in rats
According to the International Continence Society, DU is defined as a detrusor contraction of inadequate strength and/ or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying, in the absence of urethral obstruction. 91 This definition of DU implies dysfunction of the detrusor muscle. It is known that detrusor contractility diminishes with age, due to age-related degenerative changes in the detrusor muscle. 92, 93 The prevalence of DU/UAB has been found to be up to 48% of older men and up to 45% of older women undergoing urodynamic evaluation for non-neurogenic LUTS. 94 Currently, no medications or therapies have proven effective in the long-term treatment of DU/UAB, and no cure is known.
LESW has been known to facilitate tissue regeneration. We investigated the effects of LESW in a DU model, induced through cryoinjury of rat detrusor, by placing an aluminum rod (chilled with dry ice) for 30 s on the serosal side of the bladder filled with 1 mL sterile saline, bilaterally. We found that significant urodynamic, histological and molecular changes induced by the cryoinjury of rat detrusor were detected on day 8; these were reflected in a decrease in the contraction amplitude (54.3%), a significant increase in wet bladder weight (64.1%), edematous changes, muscle thinning, downregulation of a-SMA and IL-6, and upregulation of COX-2. However, LESW (0.12 mJ/mm 2 ; 200 pulses) reversed the cryoinjury-induced histological and COX-2 expression to cause a 49.0% increase in the contraction amplitude (P < 0.05). LESW-induced cell proliferation was shown through increased CD31 and Ki67 immunostaining. We suggest that LESW can afford a simple, non-invasive modality to facilitate tissue regeneration and improve voiding function in myogenic detrusor underactivity (Chuang YC, Pradeep T, Wang HJ, Huang CC, Lin CC, Chancellor MB, unpubl. data, abstract presented to American Geriatric Urology Society, May 14, 2017, Boston) . The proof of concept study might be translated into a novel physical method for the treatment of DU/UAB in humans. Furthermore, the mechanism of LESW-induced tissue regeneration might be applied to the injured sphincter and facilitate continence control after prostate-related surgery or treatment.
LESW for intravesical BoNT/A delivery
It has been shown that cystoscopic guided injections of BoNT/A have therapeutic effects on a variety of bladder disorders, including overactive bladder and interstitial cystitis/ painful bladder syndrome. 95, 96 However, injecting substances with a needle into the bladder has some limitations, including systemic leakage of the drug, hematuria, pain at the injection site and uneven distribution. 97 Therefore, there is the need to develop a simpler and lower-risk method to deliver BoNT/A, without the need for injection. It is considered that the high molecular weight (150 kDa) is a major impediment in the passive diffusion of BoNT/A from the urothelium to the suburothelium. Therefore, there is a need for physical and chemical approaches to overcome this major impediment in the delivery of BoNT/A into the deeper layers of the bladder after instillation. The use of LESW for intravesical drug delivery is predicated on reports of temporary increases in tissue permeability, after SW application and consequent increases of drug delivery into cells, without consequent cytotoxicity. 75, 76 Magnetic resonance imaging of the bladder, followed by intravesical administration of gadolinium diethylenetriamine pentaacetic acid contrast medium, showed that LESW mediated enhancement of bladder permeability to gadolinium diethylenetriamine pentaacetic acid leakage. 98 The efficacy of enhanced delivery of BoNT/A by LESW was demonstrated with a significantly reduced response (48.6%) in the intercontraction interval after AA instillation; this was 
5/0 P < 0.005 RCT compared with 71.9%, 72.6%, and 70.6% decreases with saline, saline plus LESW and BoNT/A pretreated rats, respectively. Voiding function was not compromised in any group, including the BoNT/A plus LESW group. BoNT/A plus LESW pretreated rats also showed decreases in inflammatory reaction (P < 0.05) and expression of synaptosomal-associated protein 23 (P < 0.05), synaptosomal-associated protein 25 (P = 0.061) and COX-2 (P < 0.05) compared with the control group. These results support LESW as a promising method for delivering BoNT/A, without the need for injection (Fig. 3) .
Conclusions
LESW therapy has been used clinically for musculoskeletal disorders, ischemic cardiovascular disorders and ED, through the mechanisms of neovascularization, anti-inflammation and tissue regeneration. Furthermore, LESW has been proposed to temporarily increase tissue permeability and facilitate intravesical drug delivery. Taken together, LESW might have the potential for the treatment of: (i) lower genital urinary tract inflammatory disorders, such as non-infectious cystitis or prostatitis, through the mechanisms of anti-inflammation; (ii) DU/UAB or stress urinary incontinence, through the mechanism of tissue regeneration; (iii) ED through the mechanisms of the NO pathway and neovascularization; and (iv) intravesical botulinum toxin delivery, through the mechanism of temporary increase in membrane permeability. This novel approach, using an existing technology, shows a non-invasive and promising physical method for the application of LESW in functional urological disorders. However, more advanced basic science studies and clinical trials are warranted before LESW can be widely used. 
